Biogen Idec’s Tysabri Approved for Crohn’s


Biogen Idec (NASDAQ: BIIB) of Cambridge, MA, and Ireland’s Elan announced this afternoon that the FDA has granted an expanded approval for their drug Tysabri as a treatment for Crohn’s disease. The drug was previously approved to treat multiple sclerosis.

By posting a comment, you agree to our terms and conditions.